NLRC4 and adult-onset Still disease: Recombinant human IL-18BP (or called Tadekinig Alfa) has been used for a phase II clinical trial in Europe to treat adult onset Still’s disease patients [13] and a phase III clinical trial with the experimental drug IL-18BP in patients carrying a mutation of the NOD-like receptor C4 (NLRC4) gene, characterized by severe, life threatening systemic inflammation associated with extremely high levels of IL-18 (http://www.ab2bio.com) [14] (accessed on 29 December 2022).